Nature Communications (May 2019)

The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models

  • Naiara Martínez-Vélez,
  • Marc Garcia-Moure,
  • Miguel Marigil,
  • Marisol González-Huarriz,
  • Montse Puigdelloses,
  • Jaime Gallego Pérez-Larraya,
  • Marta Zalacaín,
  • Lucía Marrodán,
  • Maider Varela-Guruceaga,
  • Virginia Laspidea,
  • Jose Javier Aristu,
  • Luis Isaac Ramos,
  • Sonia Tejada-Solís,
  • Ricardo Díez-Valle,
  • Chris Jones,
  • Alan Mackay,
  • Jose A. Martínez-Climent,
  • Maria Jose García-Barchino,
  • Eric Raabe,
  • Michelle Monje,
  • Oren J. Becher,
  • Marie Pierre Junier,
  • Elias A. El-Habr,
  • Herve Chneiweiss,
  • Guillermo Aldave,
  • Hong Jiang,
  • Juan Fueyo,
  • Ana Patiño-García,
  • Candelaria Gomez-Manzano,
  • Marta M. Alonso

DOI
https://doi.org/10.1038/s41467-019-10043-0
Journal volume & issue
Vol. 10, no. 1
pp. 1 – 10

Abstract

Read online

The oncolytic virus Delta-24-RGD is in clinical trial for adult glioma. Here, the authors show that this virus elicits an immune response in mouse models of pediatric high-grade glioma and diffuse pontine intrinsic glioma, resulting in improved survival.